RG6620 / Roche, Genentech - LARVOL DELTA

Discovery of GDC-7035, an exquisitely potent and selective KRAS G12D inhibitor in clinical development (EORTC-NCI-AACR 2026) - "Abstract will be available as of 4 November (with consent of the author)"

Clinical • Oncology • KRAS

IDEAYA entered into a clinical collaboration to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6620, Genentech's Phase 1 KRAS G12D inhibitor, in MTAP-deleted, KRAS G12D-mutant pancreatic ductal adenocarcinoma (IDEAYA Biosciences Press Release) - "Genentech will sponsor the clinical combination study, and IDEAYA will supply IDE892...IDEAYA also plans to initiate a Phase 1 combination cohort with Roche's RG6505 in MTAP-deleted, RAS-mutant PDAC in 2H 2026....Under the clinical collaboration, IDEAYA and Genentech each retain all commercial rights to their respective compounds, including as monotherapy and as combination therapies. There will be joint governance to oversee the clinical supply collaboration."

Licensing / partnership • New P1 trial • Pancreatic Ductal Adenocarcinoma

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=410 | Recruiting | Sponsor: Genentech, Inc. | Trial completion date: Nov 2028 ➔ May 2028 | Trial primary completion date: Nov 2028 ➔ May 2028

Trial completion date • Trial primary completion date • Oncology • Solid Tumor • KRAS

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=410 | Recruiting | Sponsor: Genentech, Inc. | Phase classification: P1/2 ➔ P1

Phase classification • Oncology • Solid Tumor • KRAS

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=410 | Recruiting | Sponsor: Genentech, Inc. | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor • KRAS